Fusidic acid oral - Melinta Therapeutics

Drug Profile

Fusidic acid oral - Melinta Therapeutics

Alternative Names: CEM-102; SQ-16603; Taksta

Latest Information Update: 08 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Unknown
  • Developer Cempra Pharmaceuticals; Melinta Therapeutics
  • Class Antibacterials; Cholestadienes; Sterols
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Bone and joint infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Skin and soft tissue infections
  • Phase II/III Bone and joint infections
  • No development reported Cystic fibrosis-associated respiratory tract infections; Osteomyelitis

Most Recent Events

  • 06 Nov 2017 Cempra Pharmaceuticals merged with Melinta Therapeutics to form Melinta Therapeutics
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Skin-and-soft-tissue-infections(In children) in USA (PO, Suspension)
  • 09 Aug 2017 Cempra completes enrolment in its phase II/III trial for Bone and joint infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top